doiSerbia

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis

Ristić Slobodan (Clinical Hospital Center Dr. Dragiša Mišović, Clinic of Internal Medicine, Belgrade + School of Medicine, Belgrade)
Radojković Milica (Clinical Hospital Center Dr. Dragiša Mišović, Clinic of Internal Medicine, Belgrade + School of Medicine, Belgrade)
Kostić Tatjana (Institute of Molecular Genetic and Genetic Engineering, Belgrade)
Spasovski Vesna (Institute of Molecular Genetic and Genetic Engineering, Belgrade)
Pavlović Sonja (Institute of Molecular Genetic and Genetic Engineering, Belgrade)
Čemerikić-Martinović Vesna (Beolab, Belgrade)

Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare. Case Outline. We report of a 67-year-old man with B-cell chronic lymphoid leukemia (B-CLL) who developed primary myelofibrosis (PMF) nine years after initial diagnosis. Patient received alkylation agents and purine analogue, which can be a predisposing factor for the development of myeloproliferative neoplasms. JAK2V617F mutation was not present initially at the time of CLL diagnosis, but was found after nine years when PMF occurred, which indicates that B-CLL and PMF represent two separate clonal origin neoplasms. Conclusion. Pathogenic mechanisms for the development of myeloproliferative and lymphoproliferative neoplasms in the same patient are unknown. Further research is needed to determine whether these malignancies originate from two different cell clones or arise from the same pluripotent hematopoietic stem cell.

Keywords: chronic lymphocytic leukemia, myelofibrosis, JAK2V617F mutation

Projekat Ministarstva nauke Republike Srbije, br. III 41004